Q-omics provides the consensus-scored FDPSP6 profile across patient tissues and cancer cell-line models. FDPSP6 expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FDPSP6 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, FDPSP6 RNA expression shows 4,133 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, LIHC, and STAD as cancer lineages where FDPSP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FDPSP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FDPSP6 survival associations across molecular data types. FDPSP6 RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FDPSP6 RNA expression–survival associations across cancer types. High FDPSP6 expression shows unfavorable associations in ACC, THCA, LUSC and READ, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify ACC as the clearest survival context for FDPSP6 RNA expression.
This table summarizes FDPSP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FDPSP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FDPSP6 shows higher tumor expression in LIHC. The LIHC box plot shows higher FDPSP6 RNA expression in tumor versus normal tissue (log2 FC = +0.029, t-test p = .043).
This table shows molecular features associated with FDPSP6 in patient tissues and cancer cell lines. In patient samples, FDPSP6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
